| Literature DB >> 35740146 |
Dominik Łagowski1, Sebastian Gnat1, Mariusz Dyląg2, Aneta Nowakiewicz1.
Abstract
The "One Health" concept increasingly demonstrates the global spread of pathogenic (also eukaryotic) microorganisms and their zoonotic potential. Dermatophytes can cause superficial mycoses in humans and animals. Furthermore, the number of transmissions from asymptomatic carriers to humans has been on the rise over the last few years. This study was focused on the detailed characterisation of clinical isolates of Trichophyton quinckeanum with epidemiological analyses and characterisation of their in vitro antifungal susceptibility patterns. The isolated dermatophytes were identified with a combination of conventional and molecular methods. In turn, their susceptibility in vitro was tested according to the Clinical and Laboratory Standards Institute (CLSI) M38 ed.3 protocol. A total of 36 strains were isolated, with 21 cases of T. quinckeanum zoonoses resulting from direct contact with symptomatic cats (58.3%). The other 15 strains (41.7%) were isolated simultaneously from healthy cats and their owners. All strains showed high susceptibility to allylamine, pyridinone, and phenyl morpholine derivatives but were resistant to fluconazole and ketoconazole. In conclusion, our study shows the frequency of zoonoses contracted from asymptomatic cats. Moreover, the antifungal susceptibility profiles indicate the serious risk posed to animal owners by resistant strains of T. quinckeanum, which are often responsible for recalcitrant-to-treatment cases.Entities:
Keywords: Trichophyton quinckeanum; antifungal susceptibility; asymptomatic pets; cats; diagnostics; zoonoses
Year: 2022 PMID: 35740146 PMCID: PMC9219606 DOI: 10.3390/antibiotics11060739
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Clinical isolates of Trichophyton quinckeanum examined in this study with description.
| No. of Patients | Sex | Age | Type of | Month of Isolation | Contact with Cat | Race | Leaving Home | Confirmed | Treatment | |
|---|---|---|---|---|---|---|---|---|---|---|
| Humans | Animals | |||||||||
| 1 | F | 23 | tinea capitis | April | + | European Shorthair Cat | freely | asymptomatic | Terbinafine | Miconazole, chlorhexidine |
| 2 | M | 62 | tinea corporis | March | + | Dachshund | freely | asymptomatic | Ciclopirox, terbinafine | Enilconazole |
| 3 | F | 32 | tinea capitis | April | + | Siberian Cat | freely | asymptomatic | Terbinafine | Terbinafine, chlorexidine |
| 4 | F | 80 | tinea corporis | May | + | Ragdoll | with the owner | asymptomatic | Clotrimazole, terbinafine | Terbinafine |
| 5 | M | 68 | tinea capitis | October | + | European Cat | freely | asymptomatic | Fusidic acid, ciclopirox, terbinafine | Miconazole, chlorhexidine |
| 6 | F | 79 | tinea corporis | May | + | European Cat | freely | asymptomatic | Terbinafine, ciclopirox | Miconazole, chlorhexidine |
| 7 | F | 45 | tinea corporis | July | + | Dachshund | freely | asymptomatic | Fusidic acid, ciclopirox, terbinafine | Sulphur lyme |
| 8 | M | 69 | tinea capitis | April | + | Scottish Fold | with the owner | none | Terbinafine | NA |
| 9 | F | 31 | tinea corporis | June | + | Persian | with the owner | none | Clotrimazole, terbinafine | NA |
| 10 | F | 70 | tinea corporis | May | + | British shorthair | with the owner | asymptomatic | Terbinafine, ciclopirox, clotrimazole | Enilconazole |
| 11 | F | 81 | tinea capitis | March | + | European Cat | freely | asymptomatic | Fusidic acid, ciclopirox, terbinafine | Miconazole, chlorhexidine |
| 12 | F | 52 | tinea capitis | July | + | Archangel Blue | with the owner | asymptomatic | Clotrimazole, terbinafine | Enilconazole |
| 13 | F | 74 | tinea corporis | June | + | Persian | no possibility | none | Clotrimazole, ciclopirox | NA |
| 14 | F | 69 | tinea corporis | May | + | European Cat | freely | asymptomatic | Clotrimazole, ciclopirox | Miconazole, chlorhexidine |
| 15 | M | 75 | tinea faciei | March | + | Siamese | no possibility | none | Ciclopirox, terbinafine | NA |
| 16 | M | 28 | tinea corporis | April | + | Dachshund | freely | asymptomatic | Terbinafine, ciclopirox, clotrimazole | Miconazole, chlorhexidine |
| 17 | F | 76 | tinea corporis | July | + | Sphynx | no possibility | none | Clotrimazole, terbinafine | NA |
| 18 | M | 60 | tinea capitis | November | + | Bengal cat | no possibility | none | Clotrimazole, terbinafine | NA |
| 19 | F | 32 | tinea corporis | April | + | British shorthair | with the owner | asymptomatic | Terbinafine, ciclopirox | Sulfur lyme |
| 20 | M | 40 | tinea corporis | July | + | Abyssinian cat | with the owner | asymptomatic | Clotrimazole, terbinafine | Terbinafine, chlorohexidine |
| 21 | M | 37 | tinea capitis | May | + | British Longhair | with the owner | asymptomatic | Terbinafine | Enilconazole |
F—female; M—male; NA—not applicable, the dermatophyte was not isolated from the animal; asymptomatic infection in cats was associated with the isolation of Trichophyton quinckeanum after collecting the material using the brush method; the ITS rDNA sequence with 100% similarity was obtained for each isolate from patients and animals; a sequence representative of the TQ1 isolate collected from patient no. 1 was deposited into the GenBank database, accession number MZ695772.
Figure 1Direct preparation from human skin scrapings and hairs stained with chlorazol black E (a) and calcofluor white (b) magnified 400× (Olympus BX51, Tokyo, Japan): (a) mycelium fragments indicated by arrows; (b) arthrospores indicated by green fluorescence.
Figure 2Macro- and micromorphology of Trichophyton quinckeanum isolated from humans and cats: (a,b) macromorphology on Sabouraud medium at 28 °C for 14 days: (a) obverse; (b) reverse; (c–g) macro- and microconidia in a 14-day culture preparation: (c) macro- and microconidia stained with chlorazol black E, magnification 400×; (d) microconidia, the arrow indicates the presence of a spiral hypha, chlorazol black staining, magnification 400×; (e) microconidia, chlorazol black staining, magnification 1000×; (f) macroconidia, calcofluor white fluorescent staining, magnification 400×; (g) microconidia, calcofluor white fluorescent staining, magnification 1000×.
Figure 3Macromorphological characteristics of Trichophyton quinckeanum compared with other species of dermatophytes classified under the genus Trichophyton. All photos show colonies from a 14-day culture at 25 °C. Mycological media: SAB—Sabouraud glucose agar, PDA—potato dextrose agar, MEA—malt extract agar. Designations of species of dermatophytes: 1—Trichophyton quinckeanum, 2—Trichophyton schöenleinii, 3—Trichophyton benhamiae, 4—Trichophyton mentagrophytes.
In vitro antifungal susceptibilities of clinical isolates of Trichophyton quinckeanum obtained from humans and animals.
| Antifungal Agents | Host | MIC (µg/mL) | MIC Range | MIC50 | MIC90 | MICGM | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.004 | 0.008 | 0.016 | 0.03 | 0.06 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | |||||||
| Allylamine | NFT | humans | 3 | 6 | 12 | 0.004–0.016 | 0.016 | 0.016 | 0.012 | |||||||||||
| animals | 13 | 2 | 0.008–0.016 | 0.008 | 0.008 | 0.009 | ||||||||||||||
| TRB | humans | 4 | 10 | 7 | 0.004–0.016 | 0.008 | 0.016 | 0.01 | ||||||||||||
| animals | 11 | 4 | 0.008–0.016 | 0.008 | 0.016 | 0.01 | ||||||||||||||
| Imidazoles | KTC | humans | 4 | 5 | 6 | 5 | 0.125–1 | 0.5 | 1 | 0.46 | ||||||||||
| animals | 5 | 7 | 1 | 2 | 0.125–1 | 0.25 | 1 | 0.33 | ||||||||||||
| MCZ | humans | 1 | 5 | 10 | 5 | 0.008–0.06 | 0.03 | 0.06 | 0.03 | |||||||||||
| animals | 4 | 11 | 0.016–0.03 | 0.03 | 0.03 | 0.03 | ||||||||||||||
| ENC | humans | 6 | 12 | 2 | 1 | 0.03–0.25 | 0.06 | 0.125 | 0.07 | |||||||||||
| animals | 2 | 8 | 5 | 0.03–0.125 | 0.06 | 0.125 | 0.08 | |||||||||||||
| CLT | humans | 3 | 6 | 8 | 4 | 0.06–0.5 | 0.25 | 0.5 | 0.19 | |||||||||||
| animals | 1 | 14 | 0.125–0.25 | 0.25 | 0.25 | 0.24 | ||||||||||||||
| Triazoles | ITC | humans | 7 | 9 | 4 | 1 | 0.03–0.25 | 0.06 | 0.125 | 0.07 | ||||||||||
| animals | 14 | 1 | 0.06–0.125 | 0.06 | 0.125 | 0.06 | ||||||||||||||
| FLC | humans | 2 | 6 | 7 | 3 | 3 | 2–32 | 8 | 32 | 10.85 | ||||||||||
| animals | 9 | 4 | 2 | 8–32 | 8 | 32 | 13.33 | |||||||||||||
| VRC | humans | 3 | 11 | 5 | 2 | 0.03–0.25 | 0.06 | 0.25 | 0.09 | |||||||||||
| animals | 1 | 10 | 4 | 0.03–0.125 | 0.06 | 0.125 | 0.08 | |||||||||||||
| Pyridinone derivatives | CPO | humans | 2 | 3 | 8 | 8 | 0.06–0.5 | 0.25 | 0.5 | 0.31 | ||||||||||
| animals | 4 | 9 | 2 | 0.125–0.5 | 0.25 | 0.5 | 0.25 | |||||||||||||
| Phenyl morpholine derivatives | AMR | humans | 6 | 7 | 7 | 1 | 0.008–0.06 | 0.016 | 0.03 | 0.02 | ||||||||||
| animals | 1 | 9 | 5 | 0.008–0.03 | 0.016 | 0.03 | 0.02 | |||||||||||||
Abbreviations of antifungal substances: AMR—amorolfine, CLT—clotrimazole, CPO—ciclopirox, ENC—enilconazole, FLC—fluconazole, ITC—itraconazole, KTC—ketoconazole, MCZ—miconazole, NFT—naftifine, TRB—terbinafine, VRC—voriconazole.